References analysis of the Wikipedia article "Ցիկլոֆոսֆամիդ" in the Armenian version

aspetjournals.org

jpet.aspetjournals.org

Cohen JL, Jao JY (August 1970). «Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat». The Journal of Pharmacology and Experimental Therapeutics. 174 (2): 206–10. PMID 4393764. Արխիվացված է օրիգինալից 2021 թ․ օգոստոսի 28-ին. Վերցված է 2020 թ․ հունվարի 25-ին.

cancer.gov

«NCI Drug Dictionary». National Cancer Institute. Արխիվացված օրիգինալից 2015 թ․ ապրիլի 25-ին. Վերցված է 2016 թ․ դեկտեմբերի 20-ին.

doi.org

Pagnoux C (September 2016). «Updates in ANCA-associated vasculitis». European Journal of Rheumatology. 3 (3): 122–133. doi:10.5152/eurjrheum.2015.0043. PMC 5058451. PMID 27733943.

Davis LS, Reimold AM (April 2017). «Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus». Rheumatology. 56 (suppl_1): i100–i113. doi:10.1093/rheumatology/kew417. PMC 5850311. PMID 28375452.

Gertz MA (December 2014). «Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment». American Journal of Hematology. 89 (12): 1132–40. doi:10.1002/ajh.23828. PMID 25407896.

Or-Geva N, Reisner Y (March 2016). «The evolution of T-cell depletion in haploidentical stem-cell transplantation». British Journal of Haematology. 172 (5): 667–84. doi:10.1111/bjh.13868. PMID 26684279.

Fuchs EJ (June 2015). «HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide». Bone Marrow Transplantation. 50 Suppl 2: S31–6. doi:10.1038/bmt.2015.92. PMC 4634886. PMID 26039204.

Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L (April 2016). «Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide». Seminars in Hematology. 53 (2): 90–7. doi:10.1053/j.seminhematol.2016.01.005. PMC 4806368. PMID 27000732.

Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M (September 1999). «Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?». American Journal of Medical Genetics. 86 (3): 237–41. doi:10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V. PMID 10482872.

Lohrmann HP (1984). «The problem of permanent bone marrow damage after cytotoxic drug treatment». Oncology. 41 (3): 180–4. doi:10.1159/000225819. PMID 6374556.

Singh JA, Hossain A, Kotb A, Wells G (September 2016). «Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis». BMC Medicine. 14 (1): 137. doi:10.1186/s12916-016-0673-8. PMC 5022202. PMID 27623861.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)

Malik SW, Myers JL, DeRemee RA, Specks U (December 1996). «Lung toxicity associated with cyclophosphamide use. Two distinct patterns». American Journal of Respiratory and Critical Care Medicine. 154 (6 Pt 1): 1851–6. doi:10.1164/ajrccm.154.6.8970380. PMID 8970380.

Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC (October 2005). «Cardiotoxicity of cancer therapy». Journal of Clinical Oncology. 23 (30): 7685–96. doi:10.1200/JCO.2005.08.789. PMID 16234530.

Bressler RB, Huston DP (March 1985). «Water intoxication following moderate-dose intravenous cyclophosphamide». Archives of Internal Medicine. 145 (3): 548–9. doi:10.1001/archinte.145.3.548. PMID 3977522.

Salido M, Macarron P, Hernández-García C, D'Cruz DP, Khamashta MA, Hughes GR (2003). «Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus». Lupus. 12 (8): 636–9. doi:10.1191/0961203303lu421cr. PMID 12945725.

Emadi A, Jones RJ, Brodsky RA (November 2009). «Cyclophosphamide and cancer: golden anniversary». Nature Reviews. Clinical Oncology. 6 (11): 638–47. doi:10.1038/nrclinonc.2009.146. PMID 19786984.

Monach PA, Arnold LM, Merkel PA (January 2010). «Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review». Arthritis and Rheumatism. 62 (1): 9–21. doi:10.1002/art.25061. PMID 20039416.

Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (September 1992). «Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis». Lancet. 340 (8822): 741–5. doi:10.1016/0140-6736(92)92292-n. PMID 1356175.

Pryor BD, Bologna SG, Kahl LE (September 1996). «Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus». Arthritis and Rheumatism. 39 (9): 1475–82. doi:10.1002/art.1780390906. PMID 8814058.

Suryaprasad A, Stone JH (July 2008). «When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases». Arthritis and Rheumatism. 59 (7): 1034–9. doi:10.1002/art.23822. PMID 18576286.

Kronbichler A, Jayne DR, Mayer G (March 2015). «Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis». European Journal of Clinical Investigation (Review). 45 (3): 346–68. doi:10.1111/eci.12410. PMID 25627555.

Balow JE, Austin HA, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH (January 1987). «NIH conference. Lupus nephritis». Annals of Internal Medicine. 106 (1): 79–94. doi:10.7326/0003-4819-106-1-79. PMID 3789582.

Periti P, Mazzei T, Mini E (2002). «Clinical pharmacokinetics of depot leuprorelin». Clinical Pharmacokinetics. 41 (7): 485–504. doi:10.2165/00003088-200241070-00003. PMID 12083977.

Bernatsky S, Clarke AE, Suissa S (February 2008). «Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis». Archives of Internal Medicine. 168 (4): 378–81. doi:10.1001/archinternmed.2007.107. PMID 18299492.

Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Kwoh CK (August 1995). «Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study». Arthritis and Rheumatism. 38 (8): 1120–7. doi:10.1002/art.1780380815. PMID 7639809.

Larson RA (2007). «Etiology and management of therapy-related myeloid leukemia». Hematology. American Society of Hematology. Education Program. 2007: 453–9. doi:10.1182/asheducation-2007.1.453. PMID 18024664.

Huttunen KM, Raunio H, Rautio J (September 2011). «Prodrugs--from serendipity to rational design». Pharmacological Reviews. 63 (3): 750–71. doi:10.1124/pr.110.003459. PMID 21737530.

Boddy AV, Yule SM (April 2000). «Metabolism and pharmacokinetics of oxazaphosphorines». Clinical Pharmacokinetics. 38 (4): 291–304. doi:10.2165/00003088-200038040-00001. PMID 10803453.

Wiernik PH, Duncan JH (May 1971). «Cyclophosphamide in human milk». Lancet. 1 (7705): 912. doi:10.1016/s0140-6736(71)92474-3. PMID 4102054.

Giraud, B; և այլք: (2010), «Oxazaphosphorines: new therapeutic strategies for an old class of drugs», Expert Opin Drug Metab Toxicol, 6 (8): 919–938, doi:10.1517/17425255.2010.487861, PMID 20446865.

Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D (April 2002). «Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency». Kidney International. 61 (4): 1495–501. doi:10.1046/j.1523-1755.2002.00279.x. PMID 11918757.

Koseoglu V, Chiang J, Chan KW (December 1999). «Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide». Bone Marrow Transplantation. 24 (12): 1367–8. doi:10.1038/sj.bmt.1702097. PMID 10627651.

Vigouroux D, Voltaire L (1995). «[Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]» [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Annales Francaises d'Anesthesie et de Reanimation (French). 14 (6): 508–10. doi:10.1016/S0750-7658(05)80493-9. PMID 8745976. INIST:2947795.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)

Hall AG, Tilby MJ (September 1992). «Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies». Blood Reviews. 6 (3): 163–73. doi:10.1016/0268-960X(92)90028-O. PMID 1422285.

Kohn FR, Sladek NE (October 1985). «Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines». Biochemical Pharmacology. 34 (19): 3465–71. doi:10.1016/0006-2952(85)90719-1. PMID 2996550.

Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L (July 2011). «Immunomodulatory effects of cyclophosphamide and implementations for vaccine design». Seminars in Immunopathology. 33 (4): 369–83. doi:10.1007/s00281-011-0245-0. PMID 21611872.

Friedman OM, Seligman AM (1954). «Preparation of N-Phosphorylated Derivatives of Bis-β-chloroethylamine1a». Journal of the American Chemical Society. 76 (3): 655–8. doi:10.1021/ja01632a006.

Brock N (August 1996). «The history of the oxazaphosphorine cytostatics». Cancer. 78 (3): 542–7. doi:10.1002/(SICI)1097-0142(19960801)78:3<542::AID-CNCR23>3.0.CO;2-Y. PMID 8697402.

Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O (March 2006). «Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases». BMC Infectious Diseases (անգլերեն). 6 (1): 55. doi:10.1186/1471-2334-6-55. PMC 1434751. PMID 16545113. Արխիվացված օրիգինալից 2015 թ․ նոյեմբերի 21-ին.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)

Huyan XH, Lin YP, Gao T, Chen RY, Fan YM (September 2011). «Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice». International Immunopharmacology. 11 (9): 1293–7. doi:10.1016/j.intimp.2011.04.011. PMID 21530682.

inist.fr

cat.inist.fr

nih.gov

pubmed.ncbi.nlm.nih.gov

Pagnoux C (September 2016). «Updates in ANCA-associated vasculitis». European Journal of Rheumatology. 3 (3): 122–133. doi:10.5152/eurjrheum.2015.0043. PMC 5058451. PMID 27733943.

DeVrieze BW, Hurley JA (January 2018). Goodpasture Syndrome (Anti-glomerular Basement Membrane Antibody Disease). Treasure Island, USA: StatPearls Publishing. PMID 29083697.

Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA (February 1991). «Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis». The Journal of Rheumatology. 18 (2): 188–94. PMID 1673721.

Lohrmann HP (1984). «The problem of permanent bone marrow damage after cytotoxic drug treatment». Oncology. 41 (3): 180–4. doi:10.1159/000225819. PMID 6374556.

Twohig KJ, Matthay RA (March 1990). «Pulmonary effects of cytotoxic agents other than bleomycin». Clinics in Chest Medicine. 11 (1): 31–54. PMID 1691069.

Periti P, Mazzei T, Mini E (2002). «Clinical pharmacokinetics of depot leuprorelin». Clinical Pharmacokinetics. 41 (7): 485–504. doi:10.2165/00003088-200241070-00003. PMID 12083977.

Huttunen KM, Raunio H, Rautio J (September 2011). «Prodrugs--from serendipity to rational design». Pharmacological Reviews. 63 (3): 750–71. doi:10.1124/pr.110.003459. PMID 21737530.

Boddy AV, Yule SM (April 2000). «Metabolism and pharmacokinetics of oxazaphosphorines». Clinical Pharmacokinetics. 38 (4): 291–304. doi:10.2165/00003088-200038040-00001. PMID 10803453.

Wiernik PH, Duncan JH (May 1971). «Cyclophosphamide in human milk». Lancet. 1 (7705): 912. doi:10.1016/s0140-6736(71)92474-3. PMID 4102054.

Donelli MG, Bartosek I, Guaitani A, Martini A, Colombo T, Pacciarini MA, Modica R (April 1976). «Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect». Cancer Treatment Reports. 60 (4): 395–401. PMID 1277213.

Friedman OM, Wodinsky I, Myles A (April 1976). «Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective». Cancer Treatment Reports. 60 (4): 337–46. PMID 1277209.

Colvin OM (August 1999). «An overview of cyclophosphamide development and clinical applications». Current Pharmaceutical Design. 5 (8): 555–60. PMID 10469891.

Brock N (August 1996). «The history of the oxazaphosphorine cytostatics». Cancer. 78 (3): 542–7. doi:10.1002/(SICI)1097-0142(19960801)78:3<542::AID-CNCR23>3.0.CO;2-Y. PMID 8697402.

Brock N (January 1989). «Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture». Cancer Research. 49 (1): 1–7. PMID 2491747.

ncbi.nlm.nih.gov

web.archive.org

«NCI Drug Dictionary». National Cancer Institute. Արխիվացված օրիգինալից 2015 թ․ ապրիլի 25-ին. Վերցված է 2016 թ․ դեկտեմբերի 20-ին.

«Cyclophosphamide». The American Society of Health-System Pharmacists. Արխիվացված օրիգինալից 2017 թ․ հունվարի 2-ին. Վերցված է 2016 թ․ դեկտեմբերի 8-ին.

«WHO Model List of Essential Medicines (19th List)» (PDF). World Health Organization. April 2015. Արխիվացված (PDF) օրիգինալից 2016 թ․ դեկտեմբերի 13-ին. Վերցված է 2016 թ․ դեկտեմբերի 8-ին.

«Cyclophosphamide». International Drug Price Indicator Guide. Արխիվացված օրիգինալից 2017 թ․ մայիսի 10-ին. Վերցված է 2016 թ․ դեկտեմբերի 8-ին.

«NADAC as of 2016-12-07 | Data.Medicaid.gov». Centers for Medicare and Medicaid Services. Արխիվացված օրիգինալից 2016 թ․ դեկտեմբերի 21-ին. Վերցված է 2016 թ․ դեկտեմբերի 20-ին.

Institute for Safe Medication Practices, ISMP's List of Error-Prone Abbreviations, Symbols, and Dose Designations (PDF), Արխիվացված (PDF) օրիգինալից 2011-10-27-ին.

«Archived copy». Արխիվացված օրիգինալից 2015 թ․ հունիսի 21-ին. Վերցված է 2015 թ․ հուլիսի 1-ին.{{cite web}}: CS1 սպաս․ արխիվը պատճենվել է որպես վերնագիր (link)

Ցիկլոֆոսֆամիդ (Armenian Wikipedia)

aacrjournals.org

cancerres.aacrjournals.org

archive.org

aspetjournals.org

jpet.aspetjournals.org

biomedcentral.com

cancer.gov

doi.org

drugs.com

epa.gov

inist.fr

cat.inist.fr

ismp.org

medicaid.gov

data.medicaid.gov

medicinescomplete.com

mshpriceguide.org

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

web.archive.org

who.int

worldcat.org